WO1997007813A1 - Agent de fecondite - Google Patents
Agent de fecondite Download PDFInfo
- Publication number
- WO1997007813A1 WO1997007813A1 PCT/JP1996/002412 JP9602412W WO9707813A1 WO 1997007813 A1 WO1997007813 A1 WO 1997007813A1 JP 9602412 W JP9602412 W JP 9602412W WO 9707813 A1 WO9707813 A1 WO 9707813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interleukin
- factor
- implantation
- administration
- conception
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
Definitions
- the present invention relates to a leukocyte chemotactic factor or a substance that induces the implantation of fertilized eggs by promoting the development of eggs and follicles, promoting the growth of the endometrium, and promoting the metaplasia by edema of the interstitium. It relates to a fertility promoter as an active ingredient. In particular, it relates to medical treatment for promoting conception of mammals.
- Oocytes are formed from oocytes, and oocytes are formed from oocytes through a series of developmental stages. Immediately before or immediately after birth in a mammal, the division of oocyte cells stops, and the cells become oocyte, which is a meiotic cell. When the oocyte reaches the latter half of the first meiotic prophase, chromosomal changes do not proceed without progress (first meiotic cessation), the nucleus volume increases, and the nucleus (or germinal vesicle-germinal vesicl) e). Oocytes then resume meiosis in response to the pituitary hormone gonadotropin.
- meiosis resumes in the follicle before ovulation from the ovaries and the nucleus breaks down (germina l vesicle breakdown), and the first polar body (first polar body) passes through the middle, late, and end stages of the first meiosis. The body) is released, and chromosome movement stops after reaching the second metaphase (meiosis quiescence). The second meiosis is resumed by fertilization and releases the second polar body, and meiosis is completed (Zensuke Suzuki, edited by Experimental Reproductive Physiology, 11-16, Soft Science Inc., 1982). Oocyte maturation research has been performed mainly in in vitro culture systems, and the following three methods have been adopted depending on the purpose of the experiment.
- organ culture in which the follicles including the oocytes are cultured outside the body. It is used for analysis of factors that affect oocyte maturation through or through the follicular membrane.
- the first step in conception is to have a healthy egg maturation process.
- a mature egg is an egg that releases the second polar body by fertilization, completes meiosis, establishes fertilization (fertility), and has the ability to develop (fertility) upon fertilization stimulation.
- the second half of conception is a reaction in which the fertilized egg moves through the fallopian tube and implants on the uterine wall. If there is a failure in either of these steps on the female side, conception will not be established. However, it is extremely low. Implantation is understood as the phenomenon of adhesion between the fertilized egg and the endometrium. At the time of implantation, the endometrium, the reservoir for the fertilized eggs, must be sufficiently thick and the interstitium becomes softened and softened. It has been reported that fertilized eggs are difficult to implant unless the interstitium is expanded during the ovulation period. In the case of human infertility described above, various treatments are performed depending on the cause.
- sperm that is manually collected on the day of ovulation is injected into the uterine cavity or fallopian tube, and it is expected that fertilization will be established naturally within the fallopian tube.
- the ejaculate itself is not used due to the risk of bacterial infection, and sperm washed and concentrated are used.
- In vitro fertilization and embryo transfer are performed when other treatments are not effective due to oviduct closure, oligospermia, etc., but this is done after inseminating the sperm into the egg taken out of the body and dividing it.
- the developed embryo is implanted transvaginally into the uterine wall.
- embryo transfer is performed to control the luteal phase, i.e., to form the corpus luteum, i.e., to thicken the endometrium and to degrade the interstitium.
- hormone therapy such as progesterone is performed, but the pregnancy rate is not satisfactory as mentioned above, and further improvement of the method is required.
- assisted reproductive technology A related technology collectively called assisted reproductive technology has been developed as a variant of the embryo transfer method. This includes zygote transfer into the fallopian tube before or after split fertilization after in vitro fertilization, or after split development. In addition, there is a method of transferring a gamete into the fallopian tube together with the fallopian tube. These methods are more similar to the physiological pregnancy process, but implantation of fertilized eggs has not been improved and there is room for improvement.
- Interleukin-8 stimulates IL-1, TNF, LPS, etc. from various cells such as fibroblasts and various tumor cells in addition to blood cells such as monocytes, macrophages, and lymphocytes in vivo. Is reported to be produced by Therefore, it is presumed to be an important mediator for the formation of acute inflammation, and its abnormal production is considered to be involved in some diseases. Examples include rheumatoid arthritis, gouty arthritis, asthma, sepsis, immunoangiitis, hepatitis, and pyelonephritis. However, only the detection of activity at a basic level is known, and it is not clear how it is involved in the progression of the pathological processes of those diseases.
- Interleukin-8 is a chemokine that has the effect of migrating neutrophils and lymphocytes and activating neutrophils and other mononuclear cells. Chemokine means a bioactive substance (or cytokine) that exhibits chemotaxis (or chemotaxis). Interleukin-8 is a protein consisting of 69 to 77 amino acids. ⁇ The number of amino acids varies from case to case because the N-terminus is mainly cleaved by processing by intracellular or extracellular enzymes. Interleukin-8 was first reported under the name MDNCF (K. Matsushima et al., J. Exp. Med., 167. 1883.
- Interleukin-8 is a member of the CXC chemokine family, which has a similar number of amino acids and arrangement of cysteine residues.
- the CXC chemokines have a homozygosity of about 30% at the amino acid level, and a group of low molecular weight proteins in which the positions of four cysteine residues are identical.
- other proteins belonging to the family include 7IP-10, GR0 ( ⁇ , ⁇ , r), PF-4, and NAP-10.
- CXC Chemo force-in is also called / 9 chemokine UJ Oppenheim et al., Annual. Rev. Immu nol., 9, 617, 1991).
- Monocyte chemotactic factor (hereinafter abbreviated as MCAF) is used in vivo to treat monocytes, macrophages, blood cells such as lymphocytes, fibroblasts, vascular endothelial cells, smooth muscle cells, and various tumors. It has been reported that various cells such as cells produce IL-1, TNF, IFNr, LPS, and the like upon stimulation.
- Monocyte activating factor also called MCP-1 (monocyte chemoattractant protein-1) or GDCF (glioma-derived monocyte chemotactic factor) is a protein consisting of 76 amino acids and consisting of 4 Has a cysteine residue.
- MCP-1 and GDCF are referred to as MCAF.
- MCAF is a member of the CC chemokine family, with a similar number of amino acids and arrangement of cysteine residues.
- CC chemokine family is a generic term for a group of low molecular weight proteins having homology of about 30% at the amino acid level and having the same position of four cysteine residues.
- other proteins belonging to this family include RANTES, LD78, ACT2, 1-309, MCP-2, and MCP-3 in humans, and JE and MIP-1a in mice.
- MIP-1 ⁇ , TCA-3 and the like are known as structural analogs of MCAF (N. Mukaida et al., Microbiol. Immunol., 36, 773-789, 1992).
- CC chemokine family has the feature that two cysteines are linked in the amino acid sequence on the N-terminal side.
- CC chemokine also referred to also / S- chemokine (JJOppe nheim et al, Annual Rev. Immunol., 9, 617, 1991) 0
- the present inventors have reported that administration of vaginal suppositories of interleukin-8 to rabbits causes cervical ripening (El Maradny et al., Am. J. Obstet. Gynecol., 171, 77, 1994). In other words, cervical ripening is essential for parturition, and cervical ripening is currently the most important factor in labor difficulties.
- Inflammatory cells such as neutrophils migrate into the cervix by local administration of interleukin-8, and collagen and elastase released therefrom degrade interstitial collagen and increase water content, resulting in increased cervical tract. Ripening occurs.
- interleukin-8 or MCAF The effects of interleukin-8 or MCAF on the steps of oogenesis, maturation, fertilization and conception are unknown.
- the present invention relates to a conception promoting agent containing leukocyte chemotactic factor or its inducer as an active ingredient.
- FIG. 1 shows the results of Example 1 of the present invention.
- Group A received Interleukin-8 and Group B received physiological saline.
- the horizontal axis indicates the number of fetuses per mother, and the vertical axis indicates the number of mothers holding the number of fetuses.
- FIG. 2 shows the results of Example 5 of the present invention.
- A is a control (non-administration, 0 hour) ovarian hematoxylin eosin stained section of the ovary
- B is an ovary hematoxylin eosin stained section of the ovary 10 hours after hCG administration
- C is an interleukin-8. Hematoxylin eosin-stained sections of the ovaries at 10 hours post-dose are shown, and the bars in the figure are 20 O i! D Represents
- the present inventors have focused on the fact that cytokines are involved in the ovulation process during pregnancy and that the endometrium is in a physiological inflammatory state during the implantation of a fertilized egg.
- Leukin-8 and MCAF take steps to establish pregnancy
- the conception promotion of the present invention means both steps of promotion of maturation of an unfertilized egg and promotion of implantation of a fertilized egg.
- the biological reaction is caused by locally administering leukocyte chemotactic factor in the vicinity of the endometrium, and the aim is to migrate leukocytes locally.
- leukocyte chemotactic factor is a general term for all substances that induce leukocyte chemotaxis (leukocytotaxia) in leukocytes, and refers to various substances formed in certain microorganisms and inflammatory tissues, such as interleukin-8 and similar substances. Chemokines.
- Chemokines similar to interleukin-8 are interleukin-8 families, ie, chemokines belonging to CXC chemokines (eg, GCP_2, GR0a, GRO / S, GROr, PF4, NAP-2, ENA-78, IP-10, MIG, PBP, CTAP-HI, SDF-la, SOF-1 ⁇ ) and MC AF (or MCP-1; monocyte chemotactic activator) Or monocyte chemoattractant protein 1) Family, ie, chemokines belonging to CC chemokines (eg, hMIP-la, hMIP-l / g, MCP-2, MCP-3, RANTES, I-1 309) (Drug & Development, 7, 57-65, 1996). It is known that MCA F migrates and activates monocytes and macrophages to cause physiological inflammation. In this process, interleukin-
- MCAF and analogs having this physiological effect can also be used to indirectly cause thickening of the endometrium and deterioration of the interstitium to promote implantation of fertilized eggs.
- IL-8 or MCAF it is preferable to use IL-8 or MCAF.
- substances that induce the production of leukocyte chemotactic factors such as interleukin-1, Interfuron 7 and tumor necrosis factor (TNF), platelet-activating factor (PAF), a leukocyte chemotactic substance with a similar physiological action to chemokines, and LPS, an endotoxin, are also preferably used.
- TNF tumor necrosis factor
- PAF platelet-activating factor
- LPS an endotoxin
- interleukin-8 or MCAF When interleukin-8 or MCAF is used, it can be obtained by separating and purifying naturally occurring substances by a commonly used method, for example, column chromatography, etc. It may be obtained by culturing, chemical synthesis, or gene recombination techniques. The production method is disclosed in 207778 and the like. Since these substances are already commercially available from Oncogene Science, USA, PEPR0TEC, USA, etc., they may be used.
- interleukins derived from other animals are those derived from humans or the animals to be administered, but also interleukins derived from other animals as long as they can solve the adverse effects on the human body or the body of the animals to be administered, such as the problem of an excessive immune response. It is also possible to use 8 or MCAF.
- the amino acid sequence may be substituted, inserted, deleted or modified in one or more places, or may be a peptide comprising a part of the amino acid sequence of the structure. Any substance exhibiting the activity can be used in the practice of the present invention. It is also possible to directly administer interleukin-8 or MCAF as a single component to the uterus directly, but it is also possible to use a combination of both or a combination of components with the same or similar efficacy of each substance. It can be administered.
- the dosage form of the conception-promoting agent according to the present invention is not particularly limited as long as the object of the present invention can be achieved.However, a liquid preparation such as an intrauterine spray, an ointment, a cream, a gel, or the like may be used according to a commonly used method. It can be made into semi-solids, vaginal tablets, vaginal capsules, pessaries, vaginal suppositories, and other solid preparations.
- a dosage form that can be applied to a cervical dilator such as a liquid preparation or a semi-solid preparation
- it can be administered using a cervical dilator.
- the application includes not only the case where the medicine is applied to one surface of the dilator or the like but also the case where the dipstick or the like is impregnated with the medicine by providing an appropriate impregnation means for the medicine.
- Intraperitoneal administration such as through Douglas fossa, is also possible.
- dosage forms suitable for intraperitoneal administration, intravenous administration, oral administration, and pulmonary administration can also be used.
- components generally used as additives for pharmaceutical preparations can be blended to obtain a desired dosage form.
- these components include, for example, animal and vegetable oils (soy oil, coconut oil, tallow, synthetic glyceride, etc.), hydrocarbons (liquid paraffin, squalene, solid paraffin, etc.), ester oils (octyldodecyl myristate, myristin) Isopropyl acid, etc.), higher alcohols (cetosterial alcohol, behenyl alcohol, etc.), silicon resin, silicon oil, surfactants (polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene) Fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene block copolymer, etc., water-soluble polymers (hydroxyxethyl cellulose, polyacrylic acid, carboxyxethyl cellulose, polyacrylic acid, carboxyxethyl cellulose,
- inorganic acids hydroochloric acid, phosphoric acid, etc.
- alkali metal salts of inorganic acids sodium phosphate, etc.
- inorganic bases sodium hydroxide, etc.
- organic acids lower fatty acids, citric acid, Lactic acid and the like, metal salts of organic acids (such as sodium citrate and sodium lactate), and organic bases (such as arginine and ethanolamine)
- preservatives, antioxidants and the like can be added.
- the actual additive is appropriately or in combination selected from the above depending on the dosage form of the therapeutic agent for the disease targeted by the present invention, but is not limited thereto.
- the cervical dilator in the present invention may be a synthetic resin (water-absorbent resin or thermoplastic resin, water swelling / non-swelling, water-absorbing resin or thermoplastic resin) other than plants such as Laminaria japonica.
- Substrate The material and shape are not particularly limited, as long as it can be used for the purpose in addition to the dilator made of sponge or fibrous.
- the amount of interleukin-8 and MCAF varies depending on the age of the subject female, the condition of the genital tract, such as ovarian function, the degree of endometrial thickening, and the physical condition of the subject. LO mg / kg, preferably 10 O pg to 1 mg / K g, more preferably 1 ng to 10 g / kg, but is not particularly limited to this range, but is not limited to this range. The required amount may be blended.
- the dose of other leukocyte chemotactic factor or its inducer is ultimately determined by the medical staff.
- the present invention provides the use of the compounds of the present invention in relation to pregnancy.
- the invention further provides the use of a compound of the invention in connection with medical, surgical and diagnostic procedures for promoting oocyte maturation and implantation of fertilized eggs. Therefore, the present invention can be used in a human as follows, but is not limited thereto.
- the compound of the present invention is administered before or after sexual intercourse to promote the development of the ovum, And / or promote implantation of fertilized eggs to improve pregnancy and conception.
- the invention described above can be practiced on animals other than humans.
- ⁇ Can be used for surgery and treatment.
- the purpose is to breed livestock such as horses, horses and pigs, companion animals such as dogs and cats, and wild animals such as giant topandas, tigers and rhinos. Is used.
- the breeding of these animals is beneficial to centuries, including providing good livestock meat and milk at low cost, maintaining a good pedigree, and protecting rare animals.
- the compounds of the present invention can be used in animals as follows, but are not limited thereto.
- interleukin-8 and MCAF used were provided by Dr. K. Matsushima (K. Matsushima, J. J. Oppenheim CYTOKINE, 1, 2-13, 1989).
- Rats have a diagonal uterus, and the typical number of pregnant fetuses per female is around 9-11.
- the number of pregnant fetuses in group A was 12 ⁇ 0.6, and that in group B was 10 ⁇ 1.4, indicating an increase in the number of pregnant fetuses in the group treated with interleukin-8 (P ⁇ 0.068).
- Figure 1 shows the histograms of Groups A and B.
- the interleukin-8 administration group except for one case, other animals gave birth to more than 12 fetuses per mother, and a marked improvement in the conception rate was observed.
- no rat showed abortion due to administration of interleukin-8.
- Example 2 Observation of histological changes due to interleukin-8 administration using a rat The following experiment was performed using a rat to histologically observe the effect of interleukin-8 on the endometrium. Was.
- mice Wister clean rats (female, 10 weeks old) were divided into two groups, A and B, three each.
- group A interleukin-8 administration group
- interleukin-8 was intraperitoneally injected with 1 Oig / 0.2 ml of physiological saline, and the uterus and endometrium were observed 12 hours later.
- hematoxylin-eosin staining was performed, and histological changes were observed under a microscope.
- each individual in group B (control group) was similarly injected with only 0.2 ml of physiological saline intraperitoneally, and after 12 hours, the uterus and the endometrium were observed.
- hematoxylin-eosin staining was performed, and histological changes were observed under a microscope.
- the suppository was refrigerated at 4 ° C and solidified, and inserted into the vagina of a heron for three days a day. On the 4th day, necropsy was performed, the excised uterus was visually observed, and further fixed with 10% neutral buffered formalin.
- the prepared tissue section was stained with hematoxylin-eosin, and histological changes were observed under a microscope.
- Group B control group
- a suppository consisting of only the base prepared in the same manner as Group A was inserted into the vagina of a heron, and necropsy and histological observation were performed in the same manner.
- Example 2 the endometrium in Group A was markedly swollen and edematous, and endometrial thickening was observed. It has been shown that administration of suppositories can induce similar changes during implantation of fertilized eggs in the endometrium. On the other hand, these changes were not seen at all in group B (control group).
- Example 4 Observation experiment of histological changes by MC AF in a rat
- the experiment was conducted by dividing 6 Wister clean rats (female, 10-week-old) into 2 groups, A and B, 3 each.
- Group A MC AF-administered group
- MC AF was intraperitoneally injected with 10 ng / 0.2 ml saline, and the uterus and endometrium were observed 12 hours later.
- the cells were stained with hematoxylin and eosin.
- the histological changes were observed under a microscope.
- only 0.2 ml of physiological saline was intraperitoneally injected into each individual of group B (control group), and the state of the uterus and endometrium was observed 12 hours later.
- hematoxylin and eosin staining was performed, and histological changes were observed under a microscope.
- PMSG pregnant mare serum gonadotropin
- hCG human chorionic gonadotropin
- interleukin-8 17 / zg of interleukin-8
- Fig. 2 shows a section image of the largest diameter portion of the isolated ovary. All oocytes in normal graph follicles before hCG administration had normal nuclei (Fig. 2A). At 10 hours after the administration of hCG, the nucleus had disappeared, and the majority of egg cells had extruded the primary polar body (extrude :). As shown in Figure 2B, the follicles of the rat were markedly induced by the hCG administration. Reaching is clearer than the control. This is in good agreement with the well-known results. On the other hand, even when interleukin-8 was administered instead of hCG, the development of follicles comparable to that of hCG was observed (FIG. 2C). The breakdown of the nucleus by hCG administration was 72%, and the breakdown of the nucleus by interleukin-8 administration was 54%.
- Table 1 and Table 2 show the time-dependent changes in the number of oocytes and the number of disrupted nuclei after administration of hCG or interleukin-8.
- interleukin-8 has the effect of maturing eggs comparable to hCG, reinitiating meiosis in mature follicles, disrupting the nucleus, and undergoing metaphase 1, metaphase 1, and terminal phase 1 of meiosis. The effect of releasing the monopolar body from the second metaphase to the second meiotic telogen was clearly observed.
- Example 6 In Vitro Effect of Interleukin-8 on Cumulus-Oocyte Complex Expansion
- Ovaries were excised from the rat 48 hours after PMS G administration, and the cumulus-oocyte complex was removed by puncture from individual Graf follicles, and Eagle's Minimum Essential Edition (MEM, Nissui Pharmaceutical Co. Ltd., Japan) ) This was dispersed and further collected with an i-microphone orifice, and the surface was covered with silicon oil (Aldrich Chemicals Co. USA) to prevent evaporation.
- the amount of interleukin-8 added was 10 Ong / ml.
- the ovaries were excised from the linster clean rat, and serial sections having a thickness of 4 m were prepared by the method described in Example 5. Use this section for polyclonal rat interleukin-8 ⁇
- the plate was incubated with a heron antibody (10 mg / ml) at 4 ° C.
- the sections were then washed five times with phosphate-buffered saline (pH 7.2, hereafter abbreviated as PBS), and diluted with 100-fold diluted fluorescein isothiocyanate. Incubation with G at 23 ° C for 3 hours in the dark.
- the sections were again washed with PBS, sealed with glycerin-PBS (1: 1, v / v), and observed with a fluorescence microscope (Axiophoto, Car 1 Zeiss, Germany).
- granule cells and follicular stromal cells were prepared according to the method of Li, Y-X et al. (Li, Y-X. Et al., Mol. Cell. Endocrinol., 54, 221, 1987). The outline is described below.
- the target follicle was punctured with a 28-gauge hypodermic needle, and the contents were removed into MEM medium. Cumulus-egg-free granulosa cells were collected by centrifugation. The remaining ovaries were sufficiently punctured with the same needle and washed several times to remove the remaining granulosa cells. After that, the ovarian tissue was incubated with 0.08% collagenase at 37 ° C for 5 minutes.
- the dissociated cells were discarded, and ovarian tissue fragments were further incubated with a 0.4% collagenase solution at 37 ° C for 1 hour, and follicular stromal cells were collected. These cells were dispersed at 100,000 cells / ml in MEM medium containing 5% fetal calf serum, and spread over a 4-well Labtech chamber (Nunk, Naperville, IL). Culture was started in one batch. After 24 hours, the medium was changed to a fresh medium without serum, and after culturing for another 48 hours, the above immunostaining was performed.
- Interleukin-8 was distributed to follicular cells in the ovaries before and during ovulation.
- the hCG administration increased the staining intensity.
- the distribution of interleukin-8 in the follicle was not clear.
- the follicle cells were cultured in the absence of serum to determine whether interleukin-8 was produced in the immature ovaries of the rats.
- the presence of rat interleukin-8 in the culture supernatant was strongly confirmed by ELISA and SDS-PAGE.
- interleukin-18 was particularly highly localized in the cytoplasm.
- the conception promoting effect of leukocyte chemotactic factor has been clarified.
- it has the effect of promoting the implantation of fertilized eggs into the endometrium, making it useful as a medicament and method of use in human and animal infertility treatment and artificial insemination. Indicated.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU68368/96A AU6836896A (en) | 1995-08-28 | 1996-08-28 | Fertility agent |
US08/817,941 US6013252A (en) | 1995-08-28 | 1996-08-28 | Method promoting conception by administering IL-8 or MCAF |
EP96928679A EP0790061A1 (en) | 1995-08-28 | 1996-08-28 | Fertility agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/218672 | 1995-08-28 | ||
JP21867295 | 1995-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997007813A1 true WO1997007813A1 (fr) | 1997-03-06 |
Family
ID=16723619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/002412 WO1997007813A1 (fr) | 1995-08-28 | 1996-08-28 | Agent de fecondite |
Country Status (5)
Country | Link |
---|---|
US (1) | US6013252A (ja) |
EP (1) | EP0790061A1 (ja) |
AU (1) | AU6836896A (ja) |
CA (1) | CA2203768A1 (ja) |
WO (1) | WO1997007813A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016529254A (ja) * | 2013-08-13 | 2016-09-23 | オスタラ バイオメディカル エルティーディーOstara Biomedical Ltd | 胚移植 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US20040105858A1 (en) * | 2002-08-29 | 2004-06-03 | Kim Joanne Young Hee Kwak | Diagnosis and treatment of infertility |
EP1547609A1 (en) * | 2002-09-04 | 2005-06-29 | Proteinexpress Co., Ltd. | Embryo implantation inhibitor |
US20050010183A1 (en) * | 2003-06-24 | 2005-01-13 | Weyerhaeuser Company | Absorbent structure for absorbing blood |
JP6799543B2 (ja) | 2015-01-05 | 2020-12-16 | コーネル ユニバーシティ | 哺乳類の産乳量及びリプロダクティブ・ヘルスを改善するためにil−8を使用する組成物及び方法 |
US11464831B2 (en) | 2015-01-05 | 2022-10-11 | Cornell University | Compositions and methods using IL-8 for improving health of mammals |
CN106106364B (zh) * | 2016-07-29 | 2019-03-08 | 深圳农畉农产品有限公司 | 一种提高母猪繁殖性能的养殖方法 |
CN106106363A (zh) * | 2016-07-29 | 2016-11-16 | 董标 | 一种防治种母猪细小病毒病的养殖方法 |
KR20190071722A (ko) * | 2016-09-26 | 2019-06-24 | 엠피오, 아이엔씨. | 난자, 수정란 또는 배아의 질 개선제 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753400A (ja) * | 1993-08-11 | 1995-02-28 | Eisai Co Ltd | 子宮頚管熟化剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879285A (en) * | 1986-08-22 | 1989-11-07 | Royal North Shore Hospital And Area Health Service | Fertility control |
US5179078A (en) * | 1989-05-12 | 1993-01-12 | Dana Farber Cancer Institute | Method of suppressing tumor formation in vivo |
GB9124775D0 (en) * | 1991-11-21 | 1992-01-15 | Medical Res Council | Cervical ripening |
JPH0782169A (ja) * | 1993-09-13 | 1995-03-28 | Toray Ind Inc | 創傷治療剤 |
-
1996
- 1996-08-28 WO PCT/JP1996/002412 patent/WO1997007813A1/ja not_active Application Discontinuation
- 1996-08-28 AU AU68368/96A patent/AU6836896A/en not_active Abandoned
- 1996-08-28 EP EP96928679A patent/EP0790061A1/en not_active Withdrawn
- 1996-08-28 CA CA002203768A patent/CA2203768A1/en not_active Abandoned
- 1996-08-28 US US08/817,941 patent/US6013252A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753400A (ja) * | 1993-08-11 | 1995-02-28 | Eisai Co Ltd | 子宮頚管熟化剤 |
Non-Patent Citations (6)
Title |
---|
ENDOCRINE, Vol. 3, No. 1 (1995), p. 69-79, S.C. JUNEGA, "Modulation of Mouse Spermegg Interaction"; & CHEMICAL ABSTRACTS, Vol. 122, No. 263448. * |
ENDOCRINOLOGY, Vol. 134, No. 4 (1994), p. 1788-1793; & CHEMICAL ABSTRACTS, Vol. 120, No. 267920. * |
HUM. REPROD., Vol. 8, No. 9 (1993), p. 1443-1447; & CHEMICAL ABSTRACTS, Vol. 120, No. 188113. * |
HUM. REPROD., Vol. 9, No. 1 (1994), p. 94-99; & CHEMICAL ABSTRACTS, Vol. 120, No. 295075. * |
JOURNAL OF REPRODUCTION AND FERTILITY, Vol. 98, No. 2 (1993), p. 541-548; & CHEMICAL ABSTRACTS, Vol. 119, No. 267532. * |
MEDIATORS OF INFLAMMATION, Vol. 1, No. 1 (1992), p. 67-69; & CHEMICAL ABSTRACTS, Vol. 118, No. 167058. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016529254A (ja) * | 2013-08-13 | 2016-09-23 | オスタラ バイオメディカル エルティーディーOstara Biomedical Ltd | 胚移植 |
Also Published As
Publication number | Publication date |
---|---|
US6013252A (en) | 2000-01-11 |
AU6836896A (en) | 1997-03-19 |
CA2203768A1 (en) | 1997-03-06 |
EP0790061A1 (en) | 1997-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Englert et al. | Clinical study on embryo transfer after human in vitro fertilization | |
MX2015006141A (es) | Composiciones y metodos para aumentar el rendimiento reproductivo en mamiferos no humanos utilizando una hormona foliculoestimulante recombinante (rfsh) biologicamente activa. | |
TANAKA et al. | Artificial intravaginal insemination using fresh semen in cats | |
Hashemi et al. | Efficiency of different methods of estrus synchronization followed by fixed time artificial insemination in Persian downy does | |
KR20010093276A (ko) | 불임증 치료 | |
Okano et al. | Apoptosis in the porcine uterine endometrium during the estrous cycle, early pregnancy and post partum | |
AU2794100A (en) | Treatment of infertility | |
WO1997007813A1 (fr) | Agent de fecondite | |
Rajamahendran et al. | Effect of low dose of FSH given at the beginning of the estrous cycle and subsequent superovulatory response in Holstein cows | |
von Wolff et al. | Intravaginal and intracervical application of seminal plasma in in vitro fertilization or intracytoplasmic sperm injection treatment cycles—a double-blind, placebo-controlled, randomized pilot study | |
Belaisch-Allart et al. | In vitro fertilization and embryo transfer program in Clamart, France | |
Beck et al. | A comparison of ovulation rate and late embryonic mortality in ewe lambs and ewes and the role of late embryo loss in ewe lamb subfertility | |
Sellars et al. | Time and incidence of ovulation and conception rates after incorporating estradiol cypionate into a timed artificial insemination protocol | |
Gonzalez-Bulnes et al. | Induction of the presence of corpus luteum during superovulatory treatments enhances in vivo and in vitro blastocysts output in sheep | |
Fedorka et al. | The effect of cysteine-rich secretory protein-3 and lactoferrin on endometrial cytokine mRNA expression after breeding in the horse | |
Yu et al. | Elevation in tumour necrosis factor-alpha (TNF-α) messenger RNA levels in the uterus of pregnant gilts after oestrogen treatment | |
JP2018502916A (ja) | 哺乳類の産乳量及びリプロダクティブ・ヘルスを改善するためにil−8を使用する組成物及び方法 | |
CA2124694A1 (en) | Method of treating recurrent miscarriage and improving the efficacy of assisted reproductive techniques using placental protein 14 | |
Orihuela et al. | Mating effects on female reproductive organs: the paradigm of estrogen signaling pathways in the oviduct | |
Lymberopoulos et al. | Oestrous synchronization under range conditions in dairy goats treated with different PGF2α doses during the transitional period in Greece | |
Kaya et al. | Prolonged proestrus bleeding and medical treatment in an English pointer dog | |
Bleach et al. | Effect of administration of a novel recombinant bovine interferon on length of oestrous cycle in cattle | |
Zhang et al. | Potential role for human menopausal gonadotropin in ovine superovulatory regimens during the breeding season | |
Prasad et al. | Response of post partum anestrus cows to the administration of progesterone implant and PGF2α on oestruos cyclicity | |
Aziz et al. | Comparative Efficacy of GnRH, HCG and Seminal Plasma for Induction of Ovulation During the Breeding Season in the Dromedary Camel (Camelus dromedarius). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996928679 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2203768 Country of ref document: CA Ref country code: CA Ref document number: 2203768 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 316200 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08817941 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996928679 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996928679 Country of ref document: EP |